Dr Lal PathLabs Ltd.’s fourth-quarter profit fell, missing estimates.
The diagnostic and healthcare testing services provider’s net profit fell 8% year-on-year to Rs 57 crore in the three months ended March, according to its exchange filing. That compares with the Rs 63 crore consensus estimate of analysts tracked by Bloomberg.
Sequentially, profit was up 7%.
Q4 FY23 Highlights (YoY)
Revenue rose 1% to Rs 491 crore. (Bloomberg estimate: Rs 516 crore).
Ebitda was down 5% to Rs 116 crore. (Bloomberg estimate: Rs 125 crore).
Margin contracted to 23.5% from 24.9% a year ago. (Bloomberg estimate: 24.2%).
Shares of Dr Lal PathLabs declined 1.72% after the earnings announcement, compared with a 0.18% gain in the benchmark Sensex as of 2:20 p.m. on Thursday.
WRITTEN BY
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

Myntra Profit Jumps Multifold To Rs 548 Crore In FY25


BYD Shares Fall 8% After Q2 Profit Decline


Royal Enfield's Siddhartha Lal Bats For Uniform 18% GST On All Two-Wheelers


Dr Lal PathLabs Banks On Volume Growth To Achieve 11-12% Revenue Growth In FY26
